MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:52:00Z
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
Thu 11 Jul 24, 12:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 201.47M | 168.00M | 76.13M | 62.04M | 23.62M |
| Minority interest | 0.00000M | -0.10300M | 1.51M | 3.74M | 3.60M |
| Net income | 161.52M | 164.97M | 75.03M | 61.15M | 22.37M |
| Selling general administrative | 9.93M | 8.41M | 6.42M | 3.96M | 4.81M |
| Selling and marketing expenses | 160.58M | 119.35M | 86.53M | 66.85M | 44.62M |
| Gross profit | 380.79M | 303.97M | 175.26M | 136.12M | 85.11M |
| Reconciled depreciation | 0.68M | 0.52M | 0.42M | 0.30M | 0.18M |
| Ebit | 197.85M | 167.48M | 72.84M | 59.62M | 39.49M |
| Ebitda | 198.53M | 167.99M | 73.26M | 59.92M | 39.67M |
| Depreciation and amortization | 0.68M | 0.52M | 0.42M | 0.30M | 0.18M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 197.85M | 167.48M | 72.84M | 59.62M | 23.49M |
| Other operating expenses | 256.42M | 190.09M | 133.27M | 96.74M | 68.67M |
| Interest expense | 3.61M | 0.42M | 3.30M | 2.41M | 0.14M |
| Tax provision | 39.95M | 2.93M | 1.11M | 0.88M | 1.26M |
| Interest income | 3.61M | 0.53M | 3.29M | 2.42M | 0.14M |
| Net interest income | 3.61M | 0.53M | 3.29M | 2.42M | 0.14M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 39.95M | 2.93M | 1.11M | 0.88M | 1.26M |
| Total revenue | 454.27M | 357.56M | 206.11M | 156.36M | 100.16M |
| Total operating expenses | 182.93M | 136.50M | 102.42M | 76.50M | 53.62M |
| Cost of revenue | 73.48M | 53.59M | 30.85M | 20.24M | 15.06M |
| Total other income expense net | 3.61M | 0.53M | 3.29M | 2.42M | -8.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 161.52M | 165.07M | 75.03M | 61.16M | 22.36M |
| Net income applicable to common shares | 161.52M | 164.97M | 75.03M | 61.02M | 21.84M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 863.29M | 644.41M | 478.54M | 295.76M | 218.38M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 15.00M | 13.83M | 8.40M | 1.64M | - |
| Total liab | 75.91M | 89.79M | 62.74M | 40.29M | 38.58M |
| Total stockholder equity | 787.37M | 554.62M | 415.80M | 255.47M | 179.80M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 36.84M | 50.53M | 28.06M | 16.72M | 13.21M |
| Common stock | 0.24M | 0.24M | 0.24M | 0.11M | 0.09M |
| Capital stock | 0.24M | 0.24M | 0.24M | 0.11M | 0.09M |
| Retained earnings | 693.43M | 495.51M | 333.99M | 169.02M | 93.99M |
| Other liab | - | 4.26M | 7.58M | 4.90M | 5.34M |
| Good will | - | - | - | - | - |
| Other assets | - | 7.07M | 2.10M | 3.44M | 2.27M |
| Cash | 144.41M | 97.54M | 68.14M | 68.94M | 44.73M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 64.14M | 82.02M | 51.85M | 35.03M | 32.49M |
| Current deferred revenue | 10.92M | 13.80M | 13.80M | 11.90M | 15.59M |
| Net debt | -135.39400M | -92.57800M | -64.82900M | -68.58000M | -43.98300M |
| Short term debt | 2.40M | 1.45M | 1.21M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 9.02M | 4.96M | 3.31M | 0.36M | 0.74M |
| Other stockholder equity | 95.38M | 66.36M | 82.89M | 86.00M | 85.60M |
| Property plant equipment | - | 7.37M | 5.72M | 2.13M | 2.30M |
| Total current assets | 845.33M | 629.37M | 470.11M | 289.59M | 213.21M |
| Long term investments | 0.70M | 0.60M | 0.60M | 0.60M | 0.60M |
| Net tangible assets | - | 554.62M | 415.80M | 253.96M | 176.07M |
| Short term investments | 597.19M | 449.84M | 347.78M | 191.60M | 148.63M |
| Net receivables | 43.63M | 42.09M | 33.17M | 14.07M | 10.44M |
| Long term debt | - | - | - | - | - |
| Inventory | 45.09M | 39.90M | 21.03M | 14.98M | 9.41M |
| Accounts payable | 13.97M | 16.24M | 8.78M | 6.41M | 3.70M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.67900M | -7.49300M | -1.31900M | 0.36M | 0.12M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.11M | 0.09M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 3.67M | 3.97M | 0.77M | 3.37M | 0.37M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 17.96M | 15.04M | 8.43M | 6.17M | 5.18M |
| Capital lease obligations | 9.02M | 4.96M | 4.52M | 0.36M | 0.74M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -109.47400M | -159.16700M | -42.84200M | -112.45200M | -29.73900M |
| Change to liabilities | 8.66M | 5.04M | -2.80400M | 9.76M | 5.79M |
| Total cashflows from investing activities | -109.47400M | -160.10600M | -43.30500M | -112.45200M | -29.73900M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -41.08500M | -15.02200M | -12.44200M | 70.17M | 0.19M |
| Change to operating activities | 16.15M | 7.74M | 2.18M | -7.22200M | 9.46M |
| Net income | 161.52M | 165.07M | 75.03M | 61.16M | 22.36M |
| Change in cash | 29.40M | -0.80200M | 24.21M | 20.01M | 7.13M |
| Begin period cash flow | 68.14M | 68.94M | 44.73M | 24.72M | 17.59M |
| End period cash flow | 97.54M | 68.14M | 68.94M | 44.73M | 24.72M |
| Total cash from operating activities | 181.58M | 174.88M | 79.22M | 62.21M | 36.89M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 69.78M | - |
| Depreciation | 0.68M | 0.52M | 0.42M | 0.30M | 0.18M |
| Other cashflows from investing activities | - | - | - | -111.75900M | -29.35800M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -18.87100M | -6.04300M | -5.57500M | -2.44500M | -1.89100M |
| Change to account receivables | -10.41500M | -10.54400M | -4.41600M | 0.45M | -0.57100M |
| Sale purchase of stock | -42.63700M | -35.36500M | -17.21800M | 70.17M | 0.19M |
| Other cashflows from financing activities | 1.55M | 20.34M | 4.78M | 0.39M | 0.19M |
| Change to netincome | 23.85M | 13.21M | 14.39M | 0.22M | 1.54M |
| Capital expenditures | 1.57M | 0.94M | 0.46M | 0.69M | 0.38M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -4.46800M | -3.81200M | -10.61200M | 0.54M | 4.79M |
| Stock based compensation | 24.45M | 11.96M | 12.85M | 1.56M | 1.95M |
| Other non cash items | -0.69000M | 1.91M | -0.17800M | -0.75400M | 8.19M |
| Free cash flow | 180.00M | 173.95M | 78.76M | 61.51M | 36.51M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INMD InMode Ltd |
0.10 0.56% | 17.80 | 8.76 | 7.25 | 3.08 | 1.93 | 1.59 | 3.99 |
| ABT Abbott Laboratories |
-0.469 0.44% | 106.79 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-4.36 1.28% | 336.06 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.30 0.38% | 80.27 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-1.58 2.03% | 76.18 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Tavor Building, Yokne'am, Israel, 2069206
| Name | Title | Year Born |
|---|---|---|
| Mr. Yair Malca | Chief Financial Officer | 1978 |
| Mr. Alon Yaari | VP of Operations | NA |
| Ms. Nava Tal-Launer | Chief Information Officer | NA |
| Mr. Shakil Lakhani | Pres of North America | 1983 |
| Dr. Spero Theodorou M.D. | Chief Medical Officer | 1972 |
| Mr. Moshe Mizrahy | Chairman & CEO | 1953 |
| Dr. Michael Kreindel | CTO & Director | 1968 |
| Mr. Shakil Lakhani | President of North America | 1983 |
| Mr. Alon Yaari | Vice President of Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...